Nisreen Soufi

Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial

Richard J. Thompson, Henrik Arnell, Reha Artan et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 157 citations · Full text

Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice

Angela Hall, Nisreen Soufi, Kari T. Chambers et al. · Diabetes · 2014 · 71 citations · Full text

Mogat1 Inhibition, Fatty Liver Disease, Glucose Tolerance +20

Neurodevelopmental Outcome of Young Children with Biliary Atresia and Native Liver: Results from the ChiLDReN Study

Vicky L. Ng, Lisa G. Sorensen, Estella M. Alonso et al. · The Journal of Pediatrics · 2018 · 58 citations · Full text

Developmental Biology, Early Childhood Development, Pediatrics +11

Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study

Kathleen M. Loomes, Robert H. Squires, Déirdre Kelly et al. · Hepatology Communications · 2022 · 58 citations · Full text

Pathology, Pharmacotherapy, Cholangiopathies +27

Inhibiting Monoacylglycerol Acyltransferase 1 Ameliorates Hepatic Metabolic Abnormalities but Not Inflammation and Injury in Mice

Nisreen Soufi, Angela Hall, Zhouji Chen et al. · Journal of Biological Chemistry · 2014 · 44 citations · Full text

Monoacylglycerol Acyltransferase 1, Immunology, Fatty Liver Disease +22